Notices. Correction
250 words·~1 min read·
/register/2024/03/11/2024-05081·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2020-D-1824] Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Correction. SUMMARY: The Food and Drug Administration
(FDA)is correcting a notice that appeared in the **Federal Register** on February 22, 2024. The document announced the availability of a final guidance for industry entitled “Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment.” The document was published with an incorrect docket number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: David Reasner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6373, Silver Spring, MD 20993, 301-837-7667; or James Myers, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911. SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 22, 2024 (89 FR 13351), in FR Doc. 2024-03622, the following correction is made: On page 13351, in the first column in the header of the document and in the third column in the second line of the first paragraph, “Docket No. FDA-2024-D-0584” is corrected to read “Docket No. FDA-2020-D-1824.” Dated: March 5, 2024. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2024-05081 Filed 3-8-24; 8:45 am]